JP Morgan Chase
RXRX icon

JP Morgan Chase’s Recursion Pharmaceuticals RXRX Stock Holding History

JP Morgan Chase’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.32M Sell
1,146,516
-184,037
-14% -$613K ﹤0.01% 3581
2026
Q1 		$3.78M Buy
1,330,553
+51,609
+4% +$199K ﹤0.01% 3587
2025
Q4 		$5.23M Buy
1,278,944
+859,326
+205% +$4.26M ﹤0.01% 3265
2025
Q3 		$2.05M Buy
419,618
+20,115
+5% +$106K ﹤0.01% 4068
2025
Q2 		$2.02M Sell
399,503
-418,821
-51% -$2.06M ﹤0.01% 3916
2025
Q1 		$4.33M Sell
818,324
-238,843
-23% -$1.74M ﹤0.01% 3281
2024
Q4 		$7.15M Sell
1,057,167
-119,024
-10% -$800K ﹤0.01% 3025
2024
Q3 		$7.75M Buy
1,176,191
+67,464
+6% +$484K ﹤0.01% 2835
2024
Q2 		$8.32M Buy
1,108,727
+26,622
+2% +$232K ﹤0.01% 2613
2024
Q1 		$10.8M Buy
1,082,105
+701,295
+184% +$7.81M ﹤0.01% 2409
2023
Q4 		$3.75M Sell
380,810
-574,089
-60% -$4.09M ﹤0.01% 3335
2023
Q3 		$7.3M Buy
954,899
+580,038
+155% +$5.79M ﹤0.01% 2539
2023
Q2 		$2.8M Buy
374,861
+65,347
+21% +$457K ﹤0.01% 3292
2023
Q1 		$2.06M Buy
309,514
+136,178
+79% +$1.08M ﹤0.01% 3519
2022
Q4 		$1.34M Sell
173,336
-7,802
-4% -$76.5K ﹤0.01% 3862
2022
Q3 		$1.93M Buy
181,138
+11,788
+7% +$119K ﹤0.01% 3500
2022
Q2 		$1.38M Buy
169,350
+42,311
+33% +$283K ﹤0.01% 3849
2022
Q1 		$910K Sell
127,039
-29,390
-19% -$312K ﹤0.01% 4342
2021
Q4 		$2.68M Buy
156,429
+124,826
+395% +$2.35M ﹤0.01% 3614
2021
Q3 		$727K Buy
31,603
+11,611
+58% +$329K ﹤0.01% 4514
2021
Q2 		$730K Buy
+19,992
New +$592K ﹤0.01% 4485

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JP Morgan Chase's RXRX Position: Q2 2026 in Review

JP Morgan Chase reduced its Recursion Pharmaceuticals (RXRX) stake by 14% in Q2 2026, selling an estimated $613K and leaving 1,146,516 shares worth $4.32M. The position accounts for ﹤0.01% of the portfolio, ranked #3581.

JP Morgan Chase first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. The position peaked at $10.8M in Q1 2024. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • JP Morgan Chase held 1,146,516 shares of Recursion Pharmaceuticals worth $4.32M as of Q2 2026.
  • JP Morgan Chase sold 184,037 Recursion Pharmaceuticals shares in Q2 2026, an estimated $613K.
  • Recursion Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3581 holding.
  • JP Morgan Chase first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • JP Morgan Chase's Recursion Pharmaceuticals position peaked at $10.8M in Q1 2024.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.